ERBB2 and neoplasm: HER2 protein overexpression, gene amplification, and less commonly, somatic HER2 mutations (ie, kinase domain missense and insertion mutations, extracellular domain missense mutations, and transmembrane domain mutations), drive uncontrolled cellular signalling, promoting tumour growth and survival11.